Purpose To evaluate the feasibility, safety, and efficacy of microwave ablation (MWA) of bone lesions with regard to local control and pain palliation. Materials and methods We reviewed 43 patients (23 males, 20 females) with 51 lesions (44 metastatic, 7 benign) treated with MWA from January 2016 to December 2023. Pain intensity was measured using the Visual Analogue Scale (VAS), SF-36 Bodily Pain Scale, and Patient Global Impression of Change (PGIC) from pre-operation to various follow-up stages. Adverse events were categorized according to the Society of Interventional Radiology (SIR) grading system. Results The procedure demonstrated 100% technical success. Grades I and III adverse events were observed in 8.3% (3/36) and 2.8% (1/36) of patients with metastatic disease, respectively. In those with benign lesions, no adverse events were reported. A significant reduction in pain was observed, with the VAS score decreasing by 74.3% from baseline to the last follow-up [6.7 ± 2.3 (range: 0–10) to 1.8 ± 2.3 (range: 0–7) (p < 0.001)] for metastatic patients, and from 5.7 ± 2.1 (range: 3–8) to 0 ± 0 (range: 0–0) by the final follow-up (p = 0.0011) for benign lesions. 77.8% (29/36) of metastatic patients, and all (7/7) benign patients were much or very much improved according to Patient Global Impression Change. Complete imaging response was achieved in 55.6% (20/36) of metastatic lesions. At last follow-up, 25% (9/36) had radiological evidence of recurrence, with a median recurrence time of 13 months (IQR: 8–14). Complete response was achieved in all benign lesions. Conclusions MWA is a safe and effective treatment for pain management in patients with bone lesions. Critical relevance statement This study confirms the potential of microwave ablation as a treatment for bone lesions, providing significant pain relief with a favorable safety profile. Key Points <UnorderedList Mark="Bullet"> <ItemContent> Microwave ablation (MWA) significantly reduced pain scores in patients with bone lesions, maintaining pain relief over time. </ItemContent> <ItemContent> The procedure exhibited high technical success with minimal adverse events, indicating a high safety profile. </ItemContent> <ItemContent> Subgroup analysis revealed no significant differences in pain reduction among different procedural combinations over time. </ItemContent> </UnorderedList> Graphical Abstract

Percutaneous microwave ablation of bone lesions: a retrospective cohort study

期刊论文
出版模式：

开放获取
发表日期：

2025年9月17日

查看全文

Sylvain Bodard,
Amgad M. Moussa,
Max Vaynrub,
Meredith Bartelstein,
Ernesto Santos-Martin,
Majid Maybody,
Francois H. Cornelis

摘要

Purpose

To evaluate the feasibility, safety, and efficacy of microwave ablation (MWA) of bone lesions with regard to local control and pain palliation.

Materials and methods

We reviewed 43 patients (23 males, 20 females) with 51 lesions (44 metastatic, 7 benign) treated with MWA from January 2016 to December 2023. Pain intensity was measured using the Visual Analogue Scale (VAS), SF-36 Bodily Pain Scale, and Patient Global Impression of Change (PGIC) from pre-operation to various follow-up stages. Adverse events were categorized according to the Society of Interventional Radiology (SIR) grading system.

Results

The procedure demonstrated 100% technical success. Grades I and III adverse events were observed in 8.3% (3/36) and 2.8% (1/36) of patients with metastatic disease, respectively. In those with benign lesions, no adverse events were reported. A significant reduction in pain was observed, with the VAS score decreasing by 74.3% from baseline to the last follow-up [6.7 ± 2.3 (range: 0–10) to 1.8 ± 2.3 (range: 0–7) (p < 0.001)] for metastatic patients, and from 5.7 ± 2.1 (range: 3–8) to 0 ± 0 (range: 0–0) by the final follow-up (p = 0.0011) for benign lesions. 77.8% (29/36) of metastatic patients, and all (7/7) benign patients were much or very much improved according to Patient Global Impression Change. Complete imaging response was achieved in 55.6% (20/36) of metastatic lesions. At last follow-up, 25% (9/36) had radiological evidence of recurrence, with a median recurrence time of 13 months (IQR: 8–14). Complete response was achieved in all benign lesions.

Conclusions

MWA is a safe and effective treatment for pain management in patients with bone lesions.

Critical relevance statement

This study confirms the potential of microwave ablation as a treatment for bone lesions, providing significant pain relief with a favorable safety profile.

Key Points

Microwave ablation (MWA) significantly reduced pain scores in patients with bone lesions, maintaining pain relief over time.

The procedure exhibited high technical success with minimal adverse events, indicating a high safety profile.

Subgroup analysis revealed no significant differences in pain reduction among different procedural combinations over time.

Graphical Abstract